Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03063203
Recruitment Status : Recruiting
First Posted : February 24, 2017
Last Update Posted : April 9, 2019
Sponsor:
Collaborators:
Janssen Pharmaceuticals
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Washington University School of Medicine

Brief Summary:
In this study, the investigators seek to determine whether decitabine therapy can improve outcomes, specifically overall survival this selected subset of acute myeloid leukemia (AML) patients with the poorest prognosis based on refractoriness to induction treatment and high risk genetic mutations.

Condition or disease Intervention/treatment Phase
Acute Myeloid Leukemia Acute Myeloid Leukemia, Relapsed, Adult Drug: Decitabine Procedure: Bone marrow biopsy/aspirate Procedure: Peripheral blood draw Procedure: Skin biopsy Procedure: Buccal swab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label, Multicenter, Phase II Trial Testing Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Actual Study Start Date : July 14, 2017
Estimated Primary Completion Date : July 31, 2023
Estimated Study Completion Date : July 31, 2025


Arm Intervention/treatment
Experimental: Decitabine
  • Cycle 1: All patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle
  • Cycle 2: Patients with bone marrow blast counts < 5% may receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of a 28-day cycle. All other patients will receive decitabine 20 mg/m^2 IV infusion per day over one hour on Days 1-10 of a 28-day cycle.
  • Cycle 3 and subsequent cycles: All patients will receive 20 mg/m^2 IV infusion per day over one hour on Days 1-5 of the 28-day cycle
Drug: Decitabine
  • After 2 cycles, patients with progressive disease or relapse (a clear progression with at least >20% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference
  • Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant
  • Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference
  • Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles
  • Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses
  • Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference.
Other Name: 5-aza-2'-deoxycytidine

Procedure: Bone marrow biopsy/aspirate
  • Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse
  • Biopsy/aspirate on Cycle 1 Day 10 is for participants enrolled at Washington University only
  • Biopsy/aspirate on Cycle 2 Day 28 is at the discretion of the treating physician

Procedure: Peripheral blood draw
-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse

Procedure: Skin biopsy
  • Optional but if refuse skin biopsy then participant can provided buccal swab
  • There is no required time frame for this sample - it may have been collected months or even years prior to the first dose of decitabine
  • If WBC at time of enrollment is >30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy or thereafter

Procedure: Buccal swab
-Baseline (if skin biopsy declined) and Cycle 2 Day 28




Primary Outcome Measures :
  1. Overall survival of participants with TP53 mutation [ Time Frame: 1 year ]
    • Overall survival (OS) is defined as the time from enrollment to death due to any cause. For a patient who is not known to be alive at the end of study follow up, observation of OS is censored on the date the patient was last known to be alive
    • To be evaluable for this outcome measure the participant would have to have received at least one dose of decitabine


Secondary Outcome Measures :
  1. Proportion of responding TP53 mutated patients (CR, CRi) [ Time Frame: 12 weeks ]
    • Complete remission (CR) - Defined as bone marrow blasts <5%; absence of circulating blasts and blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count >1.0 x 109/L (1,000/μL); platelet count >100 x 109/L (100,000/μL).
    • Complete remission with incomplete hematologic recovery (CRi): All CR criteria except for residual neutropenia - <1.0 x 109/L (1,000/μL) or thrombocytopenia -<100 x 109/L (100,000/μL)

  2. Time to stem cell transplant among participants who are suitable candidates for transplant and have an identified donor [ Time Frame: 12 weeks ]
    -Document the number of days that it takes each participant to reach transplant

  3. Median time to leukemia relapse (TTLR) in non-transplant patients [ Time Frame: 2 years ]
    -Recurrence/morphologic relapse - Defined as relapse following complete remission is defined as reappearance of blasts in the blood or the finding of ≥ 5% blasts in the bone marrow, not attributable to any other cause. New dysplastic changes is considered relapse. If there are no blasts in the peripheral blood and 5-20% blasts in the bone marrow, bone marrow biopsy should be repeated in > 1 week to confirm relapse.

  4. Event-free survival (EFS) [ Time Frame: 2 year ]
    -Event-free survival is defined as the interval from the date of first dose of study drug to date of treatment failure, recurrence, death due to any cause, or loss to follow up.

  5. Average number of hospital days [ Time Frame: During cycles 1 and 2 (60 days) ]
    -Document number of hospital days that each participant stays and obtain average for all evaluable participants

  6. Response compared between patients with morphologically evident disease versus patients with molecularly detected disease at the time of enrollment [ Time Frame: 12 weeks ]
    • Morphologically evident disease (>5% blasts by cytomorphology)
    • Molecularly detected disease (disease detected with flow cytometry, cytogenetic, or mutational analysis if ≤ 5% blasts by cytomorphology

  7. Survival compared between patients with morphologically evident disease versus patients with molecularly detected disease at the time of enrollment [ Time Frame: 2 years ]
    • Morphologically evident disease (>5% blasts by cytomorphology)
    • Molecularly detected disease (disease detected with flow cytometry, cytogenetic, or mutational analysis with ≤ 5% blasts by cytomorphology

  8. Response compared between patients with de novo AML versus patients with secondary AML versus patients with treatment-related AML [ Time Frame: 12 weeks ]
    -Will be described using contingency tables

  9. Survival compared between patients with de novo AML versus patients with secondary AML versus patients with treatment-related AML [ Time Frame: 2 years ]
    -Will be described using Kaplan-Meier methods and compared by log-rank test

  10. Response compared between patients with presence of cytogenetic abnormalities in addition to TP53 mutations versus patients with absence of cytogenetic abnormalities in addition to TP53 mutations [ Time Frame: 12 weeks ]
    -Will be described using contingency tables

  11. Survival compared between patients with presence of cytogenetic abnormalities in addition to TP53 mutations versus patients with absence of cytogenetic abnormalities in addition to TP53 mutations [ Time Frame: 2 years ]
    -Will be described using Kaplan-Meier methods and compared by log-rank test

  12. Median number of hospital stays [ Time Frame: During cycles 1 and 2 (60 days) ]
    -Document number of hospital days that each participant stays and obtain median for all evaluable participants



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • TP53 mutant AML. The presence of a TP53 mutation should be determined by Genoptix (or institutional preferred equivalent assay). Detection of a TP53 mutation at the time of initial diagnosis is sufficient for enrollment at the time of relapsed/refractory disease. Detection of a TP53 mutation in either the peripheral blood or bone marrow is adequate for enrollment. Alternatively, patients who have not had TP53 mutation analysis performed, but who have > 20% TP53 positive cells by immunohistochemistry detected on a bone marrow aspirate may also be enrolled,29 provided that mutation analysis is requested at the time of enrollment.
  • Relapsed/refractory AML following 7+3 (or similar cytarabine containing induction chemotherapy for AML) disease detected by one of the following methods:

    • bone marrow blasts > 5%, or
    • Hematologics flow cytometry assay (threshold > 0.5%) (alternative equivalent assay may be substituted), or
    • Persistent cytogenetic abnormality (e.g. del5, del17p, etc), by FISH or conventional karotyping, or
    • Persistent TP53 mutation (at least 5 variant reads with at least 50x coverage) determined by Genoptix (or institutional preferred equivalent assay).
  • Patients with > 10% blasts on a day +14 bone marrow biopsy following 7+3 may either be enrolled or may be treated with a course of standard re-induction (e.g. 5+2 or similar) and then re-evaluated for response. Eligible patients will meet any of the above criteria on a subsequent biopsy.
  • Bone marrow and organ function as defined below:

    • Peripheral white blood cell count < 50,000/mcl (patients may receive hydroxyurea as necessary for cytoreduction),
    • Total bilirubin < 1.5 x upper limit of normal,
    • AST and ALT < 2.5 x upper limit of normal,
    • Serum creatinine < 2.0 x upper limit of normal, and,
  • At least 18 years of age.
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately
  • Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable
  • Performance status ≤ 3

Exclusion Criteria:

  • Prior treatment with either decitabine or azacitidine or an investigational agent
  • Acute promyelocytic leukemia with PML-RARA or t(15;17).
  • History of HIV, Hepatitis B, or Hepatitis C infection.
  • Concurrent illness including, but not limited to, ongoing uncontrolled infection, symptomatic NYHA class 3 or 4 congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.
  • Radiation therapy within 14 days of enrollment.
  • Chemotherapy administration in the 7 days preceding enrollment with the exception of hydroxyurea, which can be continued until Cycle 2. A washout period for oral tyrosine kinase inhibitors (e.g. Jakafi, etc) is not required, although tyrosine kinase inhibitors therapy must be discontinued prior to enrollment.
  • Malignancies (other than AML) requiring active therapy or diagnosed within the last year, with the exception of non-melanoma skin cancer which can be treated or in situ malignancies (such as cervical, breast, prostate, etc.)
  • Currently receiving any other investigational agents.
  • Known central nervous system (CNS) leukemia or testicular involvement of leukemia
  • A history of allergic reactions attributed to compounds of similar chemical or biologic composition to decitabine or other agents used in the study.
  • Pregnant and/or breastfeeding. Women of childbearing potential must have a negative urine pregnancy test within 7 days of study entry.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03063203


Contacts
Layout table for location contacts
Contact: John Welch, M.D., Ph.D. (314) 362-2626 jwelch@wustl.edu

Locations
Layout table for location information
United States, Illinois
University of Chicago Withdrawn
Chicago, Illinois, United States, 60637
United States, Iowa
University of Iowa Not yet recruiting
Iowa City, Iowa, United States, 52242
Contact: Carlos Vigil, M.D.       carlos-vigil@uiowa.edu   
Principal Investigator: Carlos Vigil, M.D.         
United States, Massachusetts
Massachusetts General Hospital Withdrawn
Boston, Massachusetts, United States, 02114
Dana-Farber Cancer Institute Withdrawn
Boston, Massachusetts, United States, 02215
United States, Missouri
Washington University School of Medicine Recruiting
Saint Louis, Missouri, United States, 63110
Contact: John Welch, M.D., Ph.D.    314-362-2626    jwelch@wustl.edu   
Principal Investigator: John Welch, M.D., Ph.D.         
United States, Texas
The University of Texas MD Anderson Cancer Center Withdrawn
Houston, Texas, United States, 77030
United States, Washington
Fred Hutchinson Cancer Research Center Not yet recruiting
Seattle, Washington, United States, 98109
Contact: Elihu Estey, M.D.    206-288-7176    eestey@u.washington.edu   
Principal Investigator: Elihu Estey, M.D.         
Sponsors and Collaborators
Washington University School of Medicine
Janssen Pharmaceuticals
National Institutes of Health (NIH)
National Cancer Institute (NCI)
Investigators
Layout table for investigator information
Principal Investigator: John Welch, M.D., Ph.D. Washington University School of Medicine

Additional Information:
Layout table for additonal information
Responsible Party: Washington University School of Medicine
ClinicalTrials.gov Identifier: NCT03063203     History of Changes
Other Study ID Numbers: 201703089
3P50CA171963-06S1 ( U.S. NIH Grant/Contract )
First Posted: February 24, 2017    Key Record Dates
Last Update Posted: April 9, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Neoplasms
Decitabine
Antimetabolites, Antineoplastic
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors